BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 25936644)

  • 1. LKB1 Inactivation Elicits a Redox Imbalance to Modulate Non-small Cell Lung Cancer Plasticity and Therapeutic Response.
    Li F; Han X; Li F; Wang R; Wang H; Gao Y; Wang X; Fang Z; Zhang W; Yao S; Tong X; Wang Y; Feng Y; Sun Y; Li Y; Wong KK; Zhai Q; Chen H; Ji H
    Cancer Cell; 2015 May; 27(5):698-711. PubMed ID: 25936644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LKB1 Inactivation Promotes ROS-Induced Plasticity in NSCLC.
    Cancer Discov; 2015 Jul; 5(7):OF22. PubMed ID: 25977220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. YAP promotes malignant progression of Lkb1-deficient lung adenocarcinoma through downstream regulation of survivin.
    Zhang W; Gao Y; Li F; Tong X; Ren Y; Han X; Yao S; Long F; Yang Z; Fan H; Zhang L; Ji H
    Cancer Res; 2015 Nov; 75(21):4450-7. PubMed ID: 26363011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxidative stress-triggered Wnt signaling perturbation characterizes the tipping point of lung adeno-to-squamous transdifferentiation.
    Fang Z; Han X; Chen Y; Tong X; Xue Y; Yao S; Tang S; Pan Y; Sun Y; Wang X; Jin Y; Chen H; Hu L; Hui L; Li L; Chen L; Ji H
    Signal Transduct Target Ther; 2023 Jan; 8(1):16. PubMed ID: 36627278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LKB1 inactivation sensitizes non-small cell lung cancer to pharmacological aggravation of ER stress.
    Inge LJ; Friel JM; Richer AL; Fowler AJ; Whitsett T; Smith MA; Tran NL; Bremner RM
    Cancer Lett; 2014 Oct; 352(2):187-95. PubMed ID: 25011082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. cAMP/CREB-regulated LINC00473 marks LKB1-inactivated lung cancer and mediates tumor growth.
    Chen Z; Li JL; Lin S; Cao C; Gimbrone NT; Yang R; Fu DA; Carper MB; Haura EB; Schabath MB; Lu J; Amelio AL; Cress WD; Kaye FJ; Wu L
    J Clin Invest; 2016 Jun; 126(6):2267-79. PubMed ID: 27140397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer by Inducing Epidermal Growth Factor Receptor Degradation via Methionine 790 Oxidation.
    Leung EL; Fan XX; Wong MP; Jiang ZH; Liu ZQ; Yao XJ; Lu LL; Zhou YL; Yau LF; Tin VP; Liu L
    Antioxid Redox Signal; 2016 Feb; 24(5):263-79. PubMed ID: 26528827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transdifferentiation of lung adenocarcinoma in mice with Lkb1 deficiency to squamous cell carcinoma.
    Han X; Li F; Fang Z; Gao Y; Li F; Fang R; Yao S; Sun Y; Li L; Zhang W; Ma H; Xiao Q; Ge G; Fang J; Wang H; Zhang L; Wong KK; Chen H; Hou Y; Ji H
    Nat Commun; 2014; 5():3261. PubMed ID: 24531128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells.
    Kim J; Hu Z; Cai L; Li K; Choi E; Faubert B; Bezwada D; Rodriguez-Canales J; Villalobos P; Lin YF; Ni M; Huffman KE; Girard L; Byers LA; Unsal-Kacmaz K; Peña CG; Heymach JV; Wauters E; Vansteenkiste J; Castrillon DH; Chen BPC; Wistuba I; Lambrechts D; Xu J; Minna JD; DeBerardinis RJ
    Nature; 2017 Jun; 546(7656):168-172. PubMed ID: 28538732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin.
    Shackelford DB; Abt E; Gerken L; Vasquez DS; Seki A; Leblanc M; Wei L; Fishbein MC; Czernin J; Mischel PS; Shaw RJ
    Cancer Cell; 2013 Feb; 23(2):143-58. PubMed ID: 23352126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LKB1 gene inactivation does not sensitize non-small cell lung cancer cells to mTOR inhibitors in vitro.
    Xiao P; Sun LL; Wang J; Han RL; Ma Q; Zhong DS
    Acta Pharmacol Sin; 2015 Sep; 36(9):1107-12. PubMed ID: 26027660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway.
    Lin CC; Yeh HH; Huang WL; Yan JJ; Lai WW; Su WP; Chen HH; Su WC
    Am J Respir Cell Mol Biol; 2013 Aug; 49(2):241-50. PubMed ID: 23526220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced expression of liver kinase B1 and Beclin1 is associated with the poor survival of patients with non-small cell lung cancer.
    Jiang L; Liang X; Liu M; Wang W; Ma J; Guo Q; Han L; Yang C; Nan K
    Oncol Rep; 2014 Nov; 32(5):1931-8. PubMed ID: 25175672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced antitumor effect of cisplatin in human NSCLC cells by tumor suppressor LKB1.
    Ou W; Ye S; Yang W; Wang Y; Ma Q; Yu C; Shi H; Yuan Z; Zhong G; Ren J; Zhu W; Wei Y
    Cancer Gene Ther; 2012 Jul; 19(7):489-98. PubMed ID: 22576699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LKB1 promotes metabolic flexibility in response to energy stress.
    Parker SJ; Svensson RU; Divakaruni AS; Lefebvre AE; Murphy AN; Shaw RJ; Metallo CM
    Metab Eng; 2017 Sep; 43(Pt B):208-217. PubMed ID: 28034771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways.
    Han S; Khuri FR; Roman J
    Cancer Res; 2006 Jan; 66(1):315-23. PubMed ID: 16397245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FBXO22 mediates polyubiquitination and inactivation of LKB1 to promote lung cancer cell growth.
    Zhu XN; He P; Zhang L; Yang S; Zhang HL; Zhu D; Liu MD; Yu Y
    Cell Death Dis; 2019 Jun; 10(7):486. PubMed ID: 31217475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphatidylinositol ether lipid analogues induce AMP-activated protein kinase-dependent death in LKB1-mutant non small cell lung cancer cells.
    Memmott RM; Gills JJ; Hollingshead M; Powers MC; Chen Z; Kemp B; Kozikowski A; Dennis PA
    Cancer Res; 2008 Jan; 68(2):580-8. PubMed ID: 18199555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IKKα inactivation promotes Kras-initiated lung adenocarcinoma development through disrupting major redox regulatory pathways.
    Song NY; Zhu F; Wang Z; Willette-Brown J; Xi S; Sun Z; Su L; Wu X; Ma B; Nussinov R; Xia X; Schrump DS; Johnson PF; Karin M; Hu Y
    Proc Natl Acad Sci U S A; 2018 Jan; 115(4):E812-E821. PubMed ID: 29311298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence, Mechanism, and Clinical Relevance of the Transdifferentiation from Lung Adenocarcinoma to Squamous Cell Carcinoma.
    Hou S; Zhou S; Qin Z; Yang L; Han X; Yao S; Ji H
    Am J Pathol; 2017 May; 187(5):954-962. PubMed ID: 28284717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.